Customized 3D‐printed molds for high dose‐rate brachytherapy in facial skin cancer: First clinical experience
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2023
DOI: 10.1111/ddg.14944 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2023. Verfasst von Georgios Chatzikonstantinou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Oncology, University Hospital, Goethe University Frankfurt am Main, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Brachytherapy, Skin Neoplasms, Melanoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Objective Radiotherapy of elderly, frail patients with facial skin cancer in proximity to critical organs is challenging. This is the first report on clinical experience with facial skin cancer treated by individualized 3D‐printer‐based mold high‐dose‐rate (HDR) brachytherapy (BT). Patients and Methods Fifteen patients not eligible for radical surgery or definitive external beam radiotherapy (EBRT) were treated with 3D‐printer‐based mold HDR‐BT. Patient selection and treatment were in accordance with multidisciplinary tumor board recommendations. Clinical response, toxicity and cosmesis were analyzed.
Results
Median age was 77 years. Histology revealed squamous cell carcinoma in seven, basal cell carcinoma in five, melanoma in situ in one, Lentigo maligna in one, and melanoma in one patient, respectively. Median prescription dose was 39 Gy delivered in once‐daily fractions of 3 Gy. After a median follow‐up of 12.2 months, local recurrence was observed in one patient with melanoma in situ. Apart from one grade 4 cataract, no other > grade 2 late toxicity was documented.
Conclusions
HDR‐BT with 3D‐printer‐based molds for facial skin cancer is a well‐tolerated and safe treatment option for elderly, frail patients not eligible for radical surgery or definitive EBRT due to functional inoperability or tumor location.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiotherapy and Oncology, University Hospital, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
- Frankfurt Cancer Institute, Frankfurt am Main, Germany.
- Department of Dermatology, Venereology and Allergology, University Hospital, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
- German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), Partner Site Frankfurt am Main, Frankfurt am Main, Germany.
Zitieren
APA
Chatzikonstantinou, G., Diefenhardt, M., Fleischmann, M., Meissner, M., Scherf, C., Trommel, M., Ramm, U., Rödel, C., Tselis, N., & Licher, J. (2023). Customized 3D‐printed molds for high dose‐rate brachytherapy in facial skin cancer: First clinical experience. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.14944
Vancouver
Chatzikonstantinou G, Diefenhardt M, Fleischmann M, Meissner M, Scherf C, Trommel M, et al. Customized 3D‐printed molds for high dose‐rate brachytherapy in facial skin cancer: First clinical experience. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2023. doi:10.1111/ddg.14944
BibTeX
@article{Chatzikonstantinou2023,
author = {Chatzikonstantinou, Georgios and Diefenhardt, Markus and Fleischmann, Maximilian and Meissner, Markus and Scherf, Christian and Trommel, Martin and Ramm, Ulla and Rödel, Claus and Tselis, Nikolaos and Licher, Jörg},
title = {Customized 3D‐printed molds for high dose‐rate brachytherapy in facial skin cancer: First clinical experience},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2023},
doi = {10.1111/ddg.14944}
}
EUVIMED